During the past decade, we’ve seen a rapid expansion of our psoriasis knowledge and tremendous improvements in treatment methods. Better than ever, we understand the complexity of the disease and the way its comorbidities can affect people on multiple levels.
That is why the World Psoriasis & Psoriatic Arthritis Conference is among IFPA’s most important activities. We organize this conference to stimulate this knowledge expansion through discussions between experts. Every third year, the Conference gathers dermatologists, rheumatologists and allied healthcare professionals and allows them to share their most recent insights. The patient perspective is also reflected at each Conference, as IFPA’s national member associations put forward issues they believe are important to highlight on the Conference agenda.
To ensure that each Conference results in tangible achievements for the psoriasis community, we always strive to incorporate the Conference’s conclusions in our work. Past Conferences have for example successfully affected our global advocacy work, by providing input to our lobbying efforts at the World Health Organization. This resulted in the WHO adopting a Resolution on Psoriasis in 2014 and publishing a Global Report on Psoriasis two years later. Our next advocacy challenge is firmly placing psoriasis on the international non-communicable disease agenda, next to related NCDs like diabetes or cardiovascular disease. It will be interesting to incorporate the upcoming Conference’s conclusions in this project.
We already look forward to meeting you, engaging in stimulating discussions and together getting one step closer to a world free from psoriasis suffering.
Welcome to Stockholm and the IFPA World Conference 2018 –
International Federation of Psoriasis Associations
Dear Colleagues and Friends,
In 2018, Stockholm will once again welcome delegates from all over the world, for a few intense days of psoriasis discussions at the 5th World Psoriasis & Psoriatic Arthritis Conference.
During the first conference in 2006, it seemed innovative (and perhaps even controversial) to organize a conference with rheumatologists and dermatologists attending side-by-side. Since then, this setup has been widely accepted and embraced. Since then, the ambition of the conference has grown, so that today’s aim is to reflect the entire spectrum of psoriasis, including associated manifestations.
Over the past decade, we have witnessed tremendous progress in our understanding of the disease. Therapeutic strategies have developed rapidly and our treatment toolbox has been refined. This means precision medicine and tailored treatment appear within reach: ever more patients can enjoy better disease control. But still, gaps remain and new questions arise. The more we learn about psoriasis, the clearer we see how complex the disease is. That is why we must continue educating ourselves as we go along.
At the upcoming conference, we will discuss the latest psoriasis insights and developments. The program will be shaped with some valuable suggestions from IFPA members in mind. They highlighted areas of concern for patients – including treatment, safety and access. Reviewing the pros and cons of using biologics was also a suggested program item. The topic wish list is long – but this only means exciting discussions await us!
We look forward to seeing you in a summery Stockholm in 2018,
Prof. Mona Ståhle
President of the Conference
Dr. Arthur Kavanaugh and Prof. Peter van de Kerkhof
Co-Chairmen, Scientific Executive Committee